CD13 promotes hepatocellular carcinogenesis and sorafenib resistance by activating HDAC5‐LSD1‐NF‐κB oncogenic signaling

RATIONALE: CD13 is a new marker for liver cancer stem cells (CSCs) that contributes to sorafenib resistance in hepatocellular carcinoma (HCC). However, the underlying mechanism of CD13 in HCC sorafenib resistance remains enigmatic. METHODS: The expression of CD13 in HCC cell lines and tissues was as...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Bo, Xu, Yang, Li, Yuan‐Cheng, Huang, Jun‐Feng, Cheng, Jian‐Wen, Guo, Wei, Yin, Yue, Gao, Yang, Wang, Peng‐Xiang, Wu, Sui‐Yi, Zhou, Jian, Fan, Jia, Yang, Xin‐Rong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7708822/
https://www.ncbi.nlm.nih.gov/pubmed/33377659
http://dx.doi.org/10.1002/ctm2.233

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7708822/
https://www.ncbi.nlm.nih.gov/pubmed/33377659
http://dx.doi.org/10.1002/ctm2.233

Ejemplares similares